Skip to main content

Clinical outcomes in real-world patients with acute myocardial infarction receiving XIENCE V® everolimus-eluting stents: one-year results from the XIENCE V USA study.

Publication ,  Journal Article
Sudhir, K; Hermiller, JB; Naidu, SS; Henry, TD; Mao, VW; Zhao, W; Ferguson, JM; Wang, J; Jonnavithula, L; Simonton, CA; Rutledge, DR ...
Published in: Catheter Cardiovasc Interv
October 1, 2013

OBJECTIVES: The objective of this analysis was to evaluate the safety and effectiveness of XIENCE V in acute myocardial infarction (AMI). BACKGROUND: The XIENCE V(®) Everolimus-eluting coronary stent was superior to the TAXUS(®) paclitaxel-eluting stent in angiographic and clinical outcomes in the SPIRIT II, III, and IV randomized controlled trials, but patients with AMI were excluded. METHODS: XIENCE V USA is a large, prospective, multicenter, real-world single-arm postmarket surveillance trial. Consecutive patients undergoing PCI with XIENCE V were enrolled. For this analysis, clinical outcomes in 673 patients presenting with AMI (STEMI, n = 125) were as compared to patients without AMI (n = 3528) at 1 year. RESULTS: At 1 year, ARC-defined stent thrombosis (ST) rates were 1.08% in AMI vs. 0.85% in the non-AMI group (P = 0.4987). The late ST (30 days-1 year) rates were 0.31% vs. 0.47% (AMI vs. non-AMI, P = 0.7551). Rates of target lesion revascularization (TLR) were 4.1% vs. 4.6% (P = 0.6104), and rates of target lesion failure (TLF) were 9.1% vs. 8.5%, (P = 0.5964). With the historical WHO definition of MI, 1 year TLF rates were 7.0% vs. 6.7% (P = 0.8001). Improvements in quality of life, angina frequency, angina stability, and physical limitations occurred at 6 months (each P < 0.0001) and were sustained at 1 year in both groups. There were no significant differences in clinical outcomes between STEMI and non-STEMI patients. CONCLUSIONS: At 1 year, AMI patients treated with XIENCE V had low rates of ST, TLR, and TLF, similar to non-AMI patients. Marked improvements in patients' health status in this subgroup were also demonstrated.

Duke Scholars

Published In

Catheter Cardiovasc Interv

DOI

EISSN

1522-726X

Publication Date

October 1, 2013

Volume

82

Issue

4

Start / End Page

E385 / E394

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Time Factors
  • Sirolimus
  • Risk Factors
  • Prospective Studies
  • Product Surveillance, Postmarketing
  • Percutaneous Coronary Intervention
  • Myocardial Infarction
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sudhir, K., Hermiller, J. B., Naidu, S. S., Henry, T. D., Mao, V. W., Zhao, W., … XIENCE V USA Investigators. (2013). Clinical outcomes in real-world patients with acute myocardial infarction receiving XIENCE V® everolimus-eluting stents: one-year results from the XIENCE V USA study. Catheter Cardiovasc Interv, 82(4), E385–E394. https://doi.org/10.1002/ccd.24749
Sudhir, Krishnankutty, James B. Hermiller, Srihari S. Naidu, Timothy D. Henry, Vivian W. Mao, Weiying Zhao, Joanne M. Ferguson, et al. “Clinical outcomes in real-world patients with acute myocardial infarction receiving XIENCE V® everolimus-eluting stents: one-year results from the XIENCE V USA study.Catheter Cardiovasc Interv 82, no. 4 (October 1, 2013): E385–94. https://doi.org/10.1002/ccd.24749.
Sudhir K, Hermiller JB, Naidu SS, Henry TD, Mao VW, Zhao W, et al. Clinical outcomes in real-world patients with acute myocardial infarction receiving XIENCE V® everolimus-eluting stents: one-year results from the XIENCE V USA study. Catheter Cardiovasc Interv. 2013 Oct 1;82(4):E385–94.
Sudhir, Krishnankutty, et al. “Clinical outcomes in real-world patients with acute myocardial infarction receiving XIENCE V® everolimus-eluting stents: one-year results from the XIENCE V USA study.Catheter Cardiovasc Interv, vol. 82, no. 4, Oct. 2013, pp. E385–94. Pubmed, doi:10.1002/ccd.24749.
Sudhir K, Hermiller JB, Naidu SS, Henry TD, Mao VW, Zhao W, Ferguson JM, Wang J, Jonnavithula L, Simonton CA, Rutledge DR, Krucoff MW, XIENCE V USA Investigators. Clinical outcomes in real-world patients with acute myocardial infarction receiving XIENCE V® everolimus-eluting stents: one-year results from the XIENCE V USA study. Catheter Cardiovasc Interv. 2013 Oct 1;82(4):E385–E394.

Published In

Catheter Cardiovasc Interv

DOI

EISSN

1522-726X

Publication Date

October 1, 2013

Volume

82

Issue

4

Start / End Page

E385 / E394

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Time Factors
  • Sirolimus
  • Risk Factors
  • Prospective Studies
  • Product Surveillance, Postmarketing
  • Percutaneous Coronary Intervention
  • Myocardial Infarction
  • Middle Aged